Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Other financing activities (2019 - 2025)

BridgeBio Pharma's Other financing activities history spans 7 years, with the latest figure at $600000.0 for Q4 2025.

  • For Q4 2025, Other financing activities changed N/A year-over-year to $600000.0; the TTM value through Dec 2025 reached $2.2 million, up 113.45%, while the annual FY2025 figure was $2.2 million, N/A changed from the prior year.
  • Other financing activities for Q4 2025 was $600000.0 at BridgeBio Pharma, down from $1.5 million in the prior quarter.
  • Across five years, Other financing activities topped out at $2.5 million in Q1 2025 and bottomed at -$16.0 million in Q3 2024.
  • The 5-year median for Other financing activities is $277500.0 (2022), against an average of -$740333.3.
  • The largest YoY upside for Other financing activities was 251900.0% in 2025 against a maximum downside of 252100.0% in 2025.
  • A 5-year view of Other financing activities shows it stood at $734000.0 in 2021, then tumbled by 252.59% to -$1.1 million in 2022, then rose by 28.48% to -$801000.0 in 2023, then crashed by 1895.76% to -$16.0 million in 2024, then surged by 103.75% to $600000.0 in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Other financing activities are $600000.0 (Q4 2025), $1.5 million (Q3 2025), and -$2.5 million (Q2 2025).